Holen Sie sich die Stockscreener-App
7.5603
3.07%
-0.2447
Schlusskurs vom Vortag:
$7.805
Offen:
$7.98
24-Stunden-Volumen:
114.19K
Relative Volume:
1.22
Marktkapitalisierung:
$728.76M
Einnahmen:
$116.59M
Nettoeinkommen (Verlust:
$9.88M
KGV:
353.29
EPS:
0.0214
Netto-Cashflow:
$-505.00K
1W Leistung:
-1.88%
1M Leistung:
-5.67%
6M Leistung:
-3.38%
1J Leistung:
-36.75%
1-Tages-Spanne:
$7.56
$8.01
1-Wochen-Bereich:
$7.475
$8.51
52-Wochen-Spanne:
$6.11
$12.62
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(858) 567-7770
Adresse
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.565 | 751.88M | 116.59M | 9.88M | -505.00K | 0.0214 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.85 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.44 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.31 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.77 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS
Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com
Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - simplywall.st
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates - AlphaStreet
Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations - Bitget
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates - Yahoo Finance
Gyre Therapeutics Q4 revenue beats estimates on new product launch - TradingView
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases - marketscreener.com
Gyre Therapeutics reports fourth quarter and full year 2025 financial results - marketscreener.com
(GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Revenue $37.2M, vs. FactSet Est of $35.4M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS - marketscreener.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports 10% Revenue Growth in Full-Year 2025 and Announces Acquisition of Cullgen - Quiver Quantitative
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Earnings Update: Can Gyre Therapeutics Inc maintain its current growth rateJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpTime to Buy? - MarketBeat
GYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction - Yahoo Finance
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal - TipRanks
Gyre, Cullgen Merge In $300M All-Stock Deal - Law360
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 8.2%Should You Buy? - MarketBeat
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Stocktwits
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock By Investing.com - Investing.com UK
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock - Investing.com Nigeria
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger - TipRanks
Gyre Therapeutics (NASDAQ: GYRE) inks $300M all-stock Cullgen deal - Stock Titan
Gyre Therapeutics, Inc. Announces to Appoint Ying Luo as CEO, Effective March 2, 2026 - marketscreener.com
Gyre Therapeutics enters into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline - marketscreener.com
Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline - TradingView
Gyre Therapeutics to acquire Cullgen for $300 million - Investing.com
Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire
getLinesFromResByArray error: size == 0 - mfd.ru
Gyre Therapeutics, Inc. entered into an agreement to acquire Cullgen Inc. - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 111% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Risks Report: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Big Picture: How do insiders feel about Gyre Therapeutics Inc2025 Valuation Update & Trade Opportunity Analysis - baoquankhu1.vn
GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aug Selloffs: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Can Gyre Therapeutics Inc. scale operations efficientlyJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - mfd.ru
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Capitalizing on a Promising 113.78% Upside - DirectorsTalk Interviews
Market Catalysts: Can Gyre Therapeutics Inc weather a recessionTreasury Yields & Daily Entry Point Trade Alerts - baoquankhu1.vn
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):